GSE162117
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Acute myeloid leukemia patients refractory to induction therapy or relapsed within one year have poor outcomes.  Autocrine production of hepatocyte growth factor by myeloid blasts drives leukemogenesis in pre-clinical models.  A phase Ib trial evaluated ficlatuzumab, a first-in-class anti-HGF antibody, in combination with cytarabine in this high-risk population.  Dose-limiting toxicities were not observed, and 20 mg/kg was established as the recommended phase II dose.  The most frequent treatment-related adverse event was febrile neutropenia.  Among 17 evaluable patients, the overall response rate was 53%, all complete remissions.  Phospho-proteomic mass cytometry showed potent on-target suppression of p-MET after ficlatuzumab and that attenuation of p-S6 was associated with clinical response.  Multiplexed single cell RNA sequencing using longitudinally collected patient specimens identified interferon and MYC target genes as adverse predictive factors.  The ficlatuzumab and cytarabine combination is well-tolerated with favorable efficacy.  High-dimensional analyses at single-cell resolution represent promising approaches for identifying biomarkers of response and mechanisms of resistance in prospective clinical studies. Overall design: 10x Chromium based single cell RNA sequencing was performed on samples from 11 patients with refractory AML treated with ficlatuzumab and one normal control.  57 samples collected prospectively over 5 timepoints were pooled and run in 10 separate reactions.  Samples were demultiplexed based on expressed genetic variants using freemuxlet.